胰腺癌的5年生存率小于5%,中位生存期小于6个月,目前仍然是预后最差的实体肿瘤〔1〕。手术是唯一可能治愈的方法,但是大多数患者就诊时已属中晚期,只有15%~20%的患者可进行手术,术后中位生存时间11~13个月〔2〕。目前,吉西他滨(gemcitabine)作为治疗晚期胰腺癌的一线化疗用药, The 5-year survival rate of pancreatic cancer is less than 5%, the median survival time is less than 6 months, is still the worst prognosis of solid tumors 〔1〕. Surgery is the only possible cure, but most patients are already in the advanced stages of treatment, only 15% to 20% of patients undergoing surgery, the median survival time of 11 to 13 months 〔2〕. Currently, gemcitabine as a first-line chemotherapy for the treatment of advanced pancreatic cancer,